The Advent of Radioligand Therapies: A 2024 Snapshot on Prostate Cancer

About the Paper

In oncology, several biotech and pharma companies have investigated therapeutic modalities over the last few years, with the advent of immuno-oncology treatments, antibody drug conjugates, and targeted therapies. Among the modalities deployed by companies attempting to unlock the true potential of personalized medicine, radioligand therapies (RLT) are an increasingly appealing option.

Most RLT-focused companies are currently exploring the metastatic prostate cancer (mPCa) therapeutic area, where radioligand therapies have shown promising results. This interest follows the success of Novartis’ Lutathera^® (2018) and Pluvicto^® (2022), the latter specifically targeting mPCa.

This paper provides an overview of the advent of RLTs through the example of mPCa, highlighting clinical and development trends along with selected strategic considerations in key markets.